Bristol-Myers Squibb Co. (NYSE:BMY)

Big Pharma Short Interest Backs Off, With One Huge Exception

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Major Pharma Sees Tremendous Rise in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Major Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Reality Check: Big Biotech and Big Pharma Are Becoming Identical

There is great opportunity in healthcare. There is also quite a lot of risk. Politicians and consumers alike want lower drug prices. Patients want the best of the best options ...
Read Full Story »

Short Interest Spikes in a Couple Major Pharma Stocks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

The 6 Most Shorted NYSE Stocks

After one of the most brutal Decembers for stock investors in many years, we turned the calendar page on a new year. While the volatility did not go away, the ...
Read Full Story »

Why the Bristol-Myers Incredible Earnings Beat Is Getting Grounded

When Bristol-Myers Squibb Co. (NYSE: BMY) reported its most recent quarterly results before the markets opened on Thursday, the company said that it had $0.94 in earnings per share (EPS) ...
Read Full Story »

Major Pharma Sees Fading Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Thursday’s Biggest Winners and Losers in the S&P 500

January 3, 2019: The S&P 500 closed down 2.5% at 2,447.96. The DJIA closed down 2.8% at 22,686.36. Separately, the Nasdaq closed down 3.0% at 6,463.50. Thursday was a down ...
Read Full Story »

Apple, Bristol-Myers Plummet into Thursday’s 52-Week Low Club

January 3, 2019: Here are four stocks trading with heavy volume among 66 equities trading at new 52-week lows shortly before Thursday's closing bell. On the NYSE, decliners led advancers ...
Read Full Story »

Bristol-Myers, Celgene to Tie a $74 Billion Knot

There's nothing like spending $74 billion on an acquisition to get shareholders' attention. That's what Bristol-Myers Squibb Co. (NYSE: BMY) found out Thursday morning following the announcement of a definitive ...
Read Full Story »

Short Sellers Hike Bets in Major Pharma Stocks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Major Pharma Stocks See a Surge in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Major Health Care Catalysts Coming by the End of 2018

Companies in the health care sector face great risk and great reward every time they make an announcement. Drug candidates passing clinical trials, gaining regulatory approval or being canceled can ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Alphabet, American Water, Apple, Facebook, Macy’s, Southern Copper, Twitter, YY and Many More

Stocks were set to open lower on Thursday after Wednesday's market closures. The drop is on the heels of what already felt like a buyer's strike of a major sell-off ...
Read Full Story »